Name: Wuxi Biologics (Cayman) Inc. - ADR (WXXWY) Fundamental & Financial Data
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is experiencing heightened volatility following its first public earnings report, where robust revenue growth was eclipsed by investor apprehension over massive capital expenditures and an upcoming insider share lockup expiration. While the community remains deeply divided, with bulls pointing to long-term growth in AI and Starlink and bears citing valuation concerns and potential sell-offs, the immediate focus is on how institutional demand will absorb the significant influx of newly eligible shares.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are facing significant volatility after the company reported strong revenue growth and doubled data center performance, with the stock trending due to investor debates over its high valuation relative to earnings and a major strategic pivot in AI infrastructure spending. Community sentiment is deeply polarized, with bulls pointing to the company's long-term competitive expansion while bears emphasize aggressive capital expenditure and profit-taking after the stock's massive year-to-date run.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending due to a strategic overhaul of its Greater China distribution model, where the company plans to terminate thousands of third-party online resellers to regain pricing control and brand consistency. While some investors see this shift as a necessary long-term turnaround move, community sentiment remains highly polarized, with many retail shareholders expressing deep frustration over persistent price declines and the stock's multi-year underperformance.

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is seeing significant market activity as investors monitor the company's progress on its lead candidate, DURAVYU, for wet AMD, with Phase 3 LUGANO and LUCIA readouts serving as major binary catalysts. The community is actively debating the company's competitive positioning, clinical trial designs compared to Ocular Therapeutix, and institutional accumulation trends ahead of these pivotal data releases.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is facing intense retail scrutiny following a post-earnings volatility surge, with investors fiercely debating whether the stock's recent performance signals a long-term scaling opportunity or a deeper correction. The community is focused on recent guidance upgrades and major contract wins, while simultaneously grappling with heavy short interest and concerns over broader sector weakness.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is gaining attention as traders analyze its price structure against evolving liquidity and ecosystem developments, with the community actively debating whether current movements represent a consolidation phase or a precursor to further downside. Ongoing discussions highlight the platform's role in the broader altcoin market and its integration of new features, even as some participants express caution regarding market volatility and network governance.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigen is seeing significant investor attention following strong earnings and revenue projections, with the community closely tracking the commercial launch and adoption of their lead gene therapy, PAPZIMEOS. Discussions remain highly focused on the company's potential to reach cash-flow break-even, the impact of newly implemented J-code billing, and high short interest fueling anticipation for a potential short squeeze.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is currently generating significant investor interest following a strong earnings report that showcased robust revenue growth and increased guidance, though the stock has faced volatility amid market skepticism and misinformation. The community is actively debating the stock's long-term potential versus short-term price action, with many highlighting recent high-profile partnerships and technical consolidation as key signals for a potential breakout.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate its potential for a short squeeze amid high short interest and institutional accumulation, while the community actively discusses the stock's role in the enterprise AI and orchestration space. Bullish sentiment is driven by the company's strong balance sheet and pivot to agentic automation, despite ongoing skepticism and volatility surrounding the software sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as retail investors debate the stock's future amid a broader sector pullback, weighing its commercial proof points and upcoming Nasdaq transfer against technical weakness and concerns over valuation. The community remains divided between those viewing the current price as a buying opportunity based on enterprise contracts and those bracing for further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. It operates through the Biologics and XDC segments. The company was founded on February 27, 2014, and is headquartered in Wuxi, China.

Wuxi Biologics (Cayman) Inc. - ADR

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$10.21
Prev Close	$9.90
Open	$10.20
Dividend Yield	0.00%
50-Day Moving Average	$8.91
Beta	0.95
Avg. Volume	63,781.41
PE Ratio	30.50

52-Week High	$11.21
52-Week Low	$7.27
Market Capitalization	$21.15B
EPS (Annual)	$0.3391
Price to Book	3.12
Revenue Per Employee	$228,739.42

Feed

News

Sentiment

Earnings

Fundamentals

Info